GI & Endoscopy

Alexandra Read, MD, is a gastroenterologist at Puget Sound Gastroenterology in Seattle.

OrphoMed, clinical-stage biopharmaceutical company, named Mark Sostek, MD, its next CMO.

Takeda Pharmaceutical submitted a voluntary conditional takeover bid for TiGenix, a biopharmaceutical company developing stem cell therapies for anti-inflammatory disease.

Here are four practices and hospitals making headlines this past week.

Ardelyx announced that Tenapanor, a treatment for irritable bowel syndrome with constipation, completed the safety extension portion of its phase III T3MPO program.

Exact Sciences and Foundation Medicine were the top earners for the GenomeWeb Index fund in 2017, genomeweb reports.

Elisa Faybush, MD, is a gastroenterologist at Arizona Digestive Health in Mesa.

Here are four updates on GI companies from the past week:

A study, published in Journal of Digestive Disease, examined whether a new same-day, low-dose polyethylene glycol-based bowel preparation was both tolerable and effective for bowel preparation.

A study, published in Alimentary Pharmacology and Therapeutics, examined the effectiveness of adalimumab and infliximab in treating Crohn's disease patients.